etoposide + carboplatin + vincristine

Etoposide + carboplatin + vincristine is a combination chemotherapy regimen, often referred to as CEV. This regimen combines three cytotoxic agents with distinct mechanisms of action for the treatment of certain cancers, most notably small cell lung cancer (SCLC) and high-risk retinoblastoma. - **Etoposide** is a topoisomerase II inhibitor that induces DNA strand breaks, leading to apoptosis in rapidly dividing cells. - **Carboplatin** is a platinum-based compound that forms DNA crosslinks and inhibits DNA synthesis and function, resulting in cell death. - **Vincristine** is a vinca alkaloid that disrupts microtubule formation during mitosis, arresting cell division. The combination leverages the complementary mechanisms of these drugs to enhance antineoplastic activity while managing toxicity profiles; for example, vincristine's low myelosuppressive potential allows its use alongside other myelosuppressive agents[1][2][4]. The regimen has demonstrated high response rates and manageable toxicity in SCLC[1][2], as well as efficacy in preventing metastasis after enucleation in high-risk retinoblastoma[4].

Brand names

CEV

Other names

CEV